Search Results
Sep 10, 2026, 10:15 ET Revenue Cycle Management Market worth $132.06 billion by 2031 - Exclusive Report by MarketsandMarkets™
& VNA, Telehealth, RCM, CDSS, LIS), Nonclinical (Analytics, RCM, Pharmacy, Interoperability), Service (Claim, Billing, Supply)], End User (Hospital, ASC, Pharmacy, Payer) - Global Forecast to 2031
More news about: MarketsandMarkets
Sep 09, 2026, 10:00 ET Milagro Expands Role with Constitution Surgery Alliance, Adding Clinical Data Extraction to Autonomous Coding Platform
highest level of surgical care to patients undergoing high-acuity and complex surgeries. CSA partnered ASCs have won the prestigious Leapfrog Group "Top ASC" award seventeen times. For more information about Constitution Surgery Alliance and our award winning ASCs, please visit
More news about: Milagro
Sep 09, 2026, 09:25 ET Bloomberg Tax Collaborates with DMI to Streamline Uncertain Tax Position Workflows
Decision Modeling, Inc. has been the premier provider of software solutions for federal and state interest and penalty software and uncertain tax positions (ASC 740 - 10 and FIN 48). Our clients include Fortune 500 companies, national accounting firms, federal government agencies and premier law firms. DMI'
More news about: Bloomberg Tax
Sep 08, 2026, 09:00 ET Davie Defense Continues to Strengthen U.S. Leadership with Appointment of Bill Rebarick as President
a pivotal time for Davie Defense as the company advances major U.S. shipbuilding programs, including the U.S. Coast Guard's Arctic Security Cutter (ASC) program, and invests in the modernization and expansion of its Gulf Copper facilities in Galveston and Port Arthur.Rebarick said: "I'm excited
More news about: Davie Defense
Sep 08, 2026, 06:10 ET Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R
More news about: Ascletis Pharma Inc.
Sep 08, 2026, 06:10 ET 歌禮宣布在美國啟動口服胰澱素受體激動劑多肽ASC36治療肥胖症的I期研究
在一項頭對頭飲食誘導肥胖（DIO）大鼠模型中，與eloralintide和petrelintide注射劑相比，ASC36皮下注射劑實現的減重效果分別相對提升約32%和91%。- 基於潛在更優的口服生物利用度和療效，預計ASC36口服片的給藥劑量更低。ASC36多肽這一每毫克更優越的減重效果，也可能使其在規模化生產中成本更低。香港2026年9月8日 /美通社/ -- 歌禮
More news about: 歌禮製藥有限公司
Sep 07, 2026, 15:33 ET /C O R R E C T I O N -- Reliable Safety & Flow Corporation/
In the news release, Reliable Automatic Sprinkler Company and ASC Engineered Solutions Unite as Reliable Safety & Flow Corporation, issued 02-Sep-2026 by Reliable Safety & Flow Corporation over PR Newswire, we are advised by the company that changes have been made. The complete, corrected
More news about: Reliable Safety & Flow Corporation
Sep 07, 2026, 00:15 ET Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R
More news about: Ascletis Pharma Inc.
Sep 07, 2026, 00:15 ET 歌禮宣佈獲納入滬港通及深港通計劃項下的港股通名單
Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款每日一次口服小分子GLP-1R激動劑，用於長期體重管理和糖尿病治療；ASC30_48FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC48（GIPR激動劑）的固定劑量復方制劑；ASC30_48_39FDC，一款每日一次口服小分子三靶點激動劑，為ASC30（GLP-1R激動劑）、ASC48（GIPR激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC39，一款與eloralint
More news about: 歌禮製藥有限公司
Sep 03, 2026, 13:01 ET Ric Burns' Acclaimed NEW YORK: A DOCUMENTARY FILM Returns with Two New Films September 21st and 22nd On PBS
Chih Hsuan Liang, Omry Maoz, Margaret Metzger, Tom Patterson, Joshua Woltermann, Michael Craft and Li-Shin Yu), with cinematography by Buddy Squires ASC and music by Brian Keane. For The WNET Group, Stephen Segaller is executive in charge and Benjamin Phelps is senior producer. The films are part of the
More news about: The WNET Group
Sep 03, 2026, 10:30 ET Radiation Dose Management Market worth $0.96 billion by 2031 - Exclusive Report by MarketsandMarkets™
& VNA, Telehealth, RCM, CDSS, LIS), Nonclinical (Analytics, RCM, Pharmacy, Interoperability), Service (Claim, Billing, Supply)], End User (Hospital, ASC, Pharmacy, Payer) - Global Forecast to 2031About MarketsandMarkets™MarketsandMarkets™ has been recognized as one of America's Best
More news about: MarketsandMarkets
Sep 02, 2026, 08:25 ET Genesis Innovation Group Appoints Patrick Jamnik as Chief of Staff
Sterile Processing Express (SPDx), now Instrumentum – a specialty service provider of off-site sterilization services for joint replacement at ASC, now currently servicing customers in the southwestern US.Embody –
More news about: Genesis Innovation Group
Sep 01, 2026, 13:00 ET Yellow Wood Partners Agrees to Acquire Nestle's Holistic Health Platform of Leading Vitamins, Minerals and Supplements Brands
www.yellowwoodpartners.comContactsYellow Wood Partners LLC ASC AdvisorsSteve Bruce / Taylor Ingraham / Kylie Souder+1 (203) 992-1230
More news about: Yellow Wood Partners
Aug 31, 2026, 14:34 ET Colorado Urology Names Megan Rood Chief Executive Officer
Experienced Colorado healthcare leader brings more than 20 years of physician practice and ASC leadership experience to support continued growth and patient-centered careDENVER, Aug. 31, 2026 /PRNewswire/
More news about: Colorado Urology
Aug 30, 2026, 06:15 ET Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R
More news about: Ascletis Pharma Inc.
Aug 30, 2026, 06:15 ET 歌禮宣布每日一次口服小分子GLP-1受體激動劑ASC30用於長期體重管理的全球III期臨床項目完成首例受試者給藥
香港2026年8月30日 /美通社/ -- 歌禮制藥有限公司（香港聯交所代碼：1672，簡稱「歌禮」）宣布，ASC30用於長期體重管理的全球III期臨床項目已完成首例受試者給藥。ASC30是一款歌禮專有的、正在臨床研究中的每日一次口服小分子胰高血糖素樣肽-1受體（GLP-1R）激動劑，開發用於長期體重管理和糖尿病治療。
More news about: 歌禮製藥有限公司
Aug 28, 2026, 10:15 ET mHealth Solutions Market worth $275.44 billion by 2031 - Exclusive Report by MarketsandMarkets™
& VNA, Telehealth, RCM, CDSS, LIS), Nonclinical (Analytics, RCM, Pharmacy, Interoperability), Service (Claim, Billing, Supply)], End User (Hospital, ASC, Pharmacy, Payer) - Global Forecast to 2031
More news about: MarketsandMarkets
Aug 27, 2026, 16:01 ET AUTODESK, INC. ANNOUNCES FISCAL 2027 SECOND QUARTER RESULTS
Moreover, because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use under FASB ASC Topic 718, Autodesk believes that excluding stock-based compensation expenses allows investors to make meaningful comparisons between its recurring core
More news about: Autodesk, Inc.
Aug 27, 2026, 10:09 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 28, 2026 in Hub Group, Inc. Lawsuit - HUBG
stating that revenue was recognized "when we transfer services to our customers in an amount that reflects the consideration we expect to receive" under ASC Topic 606. Each filing also contained certifications from the CEO and CFO stating that disclosure controls and procedures were "effective" and that financial
More news about: SueWallSt.com
Aug 27, 2026, 08:00 ET Ardmore Shipping Exercises Newbuilding Options
HAMILTON, Bermuda, Aug. 27, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced it has exercised the options for a further two 40,500 dwt Handysize product/chemical tankers to be built
More news about: Ardmore Shipping Corporation
Aug 26, 2026, 10:15 ET Medical Image Analysis Software Market worth $6.42 billion by 2031 - Exclusive Report by MarketsandMarkets™
& VNA, Telehealth, RCM, CDSS, LIS), Nonclinical (Analytics, RCM, Pharmacy, Interoperability), Service (Claim, Billing, Supply)], End User (Hospital, ASC, Pharmacy, Payer) - Global Forecast to 2031
More news about: MarketsandMarkets
Aug 25, 2026, 05:00 ET Vipshop Reports Unaudited Second Quarter 2026 Financial Results
that cash flows for the period presented and the detailed footnote disclosures required by Accounting Standards Codification 270, Interim Reporting ("ASC270") have been omitted. Vipshop uses non-GAAP net income attributable to Vipshop's shareholders, non-GAAP net income attributable to Vipshop's shareholders
More news about: Vipshop Holdings Limited
Aug 24, 2026, 08:30 ET Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
HERE.Media Contact:ASC AdvisorsTaylor Ingraham / Max [email protected] /
More news about: Jorey Chernett
Aug 20, 2026, 13:05 ET Lost Money on Hub Group, Inc. (HUBG)? A Class Action Suit is Seeking Recovery - Contact SueWallSt
further alleges Hub Group prematurely or incorrectly recognized revenue on certain transactions that were not adequately supported. Under ASC Topic 606, the Company was required to recognize revenue based on relative transit time as control transferred to customers. The lawsuit asserts that
More news about: SueWallSt.com
Aug 20, 2026, 07:20 ET Yunji Announces First Half 2026 Unaudited Financial Results
plans. Adjusted net loss enables management to assess operating performance without considering the impact of share-based compensation recorded under ASC 718, "Compensation-Stock Compensation." The Company also believes that the use of this non-GAAP measure facilitates investors' assessment of operating
More news about: Yunji Inc.